All Resources

Overview of the factors playing a role in the etiology of T1D.

Explore how clinical outcomes are impacted by screening and monitoring

The number, type, and titer of islet autoantibodies detected in T1D screening tests provide valuable information about potential progression to clinical T1D. 

Monitoring people with early-stage autoimmune T1D may reduce the risk of serious complications, such as DKA.

Type 1 diabetes is underpinned by autoimmune activity against insulin-producing beta cells, as explained in this video.

Expert consensus on monitoring individuals with T1D islet autoantibodies: detection, monitoring frequency, and psychosocial support for managing autoimmune T1D.

Expert consensus on monitoring individuals with T1D islet autoantibodies: detection, monitoring frequency, and psychosocial support for managing autoimmune T1D.

Screening for autoimmune T1D involves testing for autoantibodies that are markers of destruction of insulin-producing beta cells.

The burden associated with a diagnosis of autoimmune T1D can be wide-ranging. This video describes the impact of diagnosis on an individual and their family.

Why and Who: an overview of the key considerations and decisions that inform screening people for islet autoantibodies.